Heart Failure: An Update from the Last Years and a Look at the Near Future
Key result
SGLT2 inhibitors and ferric derisomaltose lead heart failure advances despite non-significant mortality or rehospitalization reductions.
- 95% CI 0.66-1.02
- P=0.070
Why the study?
Major progress has occurred in heart failure management across the ejection fraction spectrum and in decompensated heart failure, warranting an update on recent advances and upcoming therapies.
Design
Review article
Authors
Discussion
Loading...
Member takes
Implication
SGLT2 inhibitors extend to HFpEF while ferric derisomaltose shows a nonsignificant trend; leaves open optimal iron strategies in heart failure.
Structured PICO
P
Population
Patients with heart failure across the spectrum of ejection fractions (HFrEF, HFpEF) and acute decompensated heart failure.
I
Intervention
Various heart failure therapies including quadruple therapy, verciguat, omecamtiv mecarbil, potassium-lowering agents, SGLT2 inhibitors, acetazolamide, hydrochlorothiazide, torasemide, ferric derisomaltose, and device therapies.
This review highlights recent major advancements in heart failure management, including the establishment of quadruple therapy for HFrEF and the proven efficacy of SGLT2 inhibitors across the entire spectrum of ejection fractions.
Cite This Study
Riccardi et al. (2022) conducted a review in Heart failure. Heart failure therapies was evaluated. Recent advances in heart failure management include SGLT2 inhibitors for HFpEF and ferric derisomaltose for cardiovascular mortality or rehospitalizations (rate ratio 0.82; 95% CI 0.66-1.02; P=0.070).